Technology

Galmed Pharmaceuticals

$3.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+0.80%) Today
-$0.06 (-1.59%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell GLMD and other stocks, options, and ETFs commission-free!

About GLMD

Galmed Pharmaceuticals Ltd. Ordinary Shares, also called Galmed Pharmaceuticals, is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel. The listed name for GLMD is Galmed Pharmaceuticals Ltd. Ordinary Shares.

CEO
Allen Baharaff
Employees
21
Headquarters
Tel Aviv, Tel Aviv
Founded
2000
Market Cap
80.56M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
131.98K
High Today
$3.82
Low Today
$3.66
Open Price
$3.78
Volume
139.63K
52 Week High
$6.44
52 Week Low
$2.96

Collections

GLMD Earnings

-$0.39
-$0.26
-$0.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

CMCL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure